Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPXGet Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 457,500 shares, an increase of 90.3% from the December 31st total of 240,400 shares. Based on an average trading volume of 3,640,000 shares, the short-interest ratio is currently 0.1 days. Approximately 3.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

View Our Latest Research Report on Virpax Pharmaceuticals

Virpax Pharmaceuticals Trading Down 3.5 %

NASDAQ:VRPX opened at $0.31 on Friday. The company has a fifty day moving average of $0.36 and a 200 day moving average of $0.68. Virpax Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $5.48.

Hedge Funds Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC purchased a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPXFree Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Company Profile

(Get Free Report)

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

See Also

Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.